# Value Radar: Fresh Picks & Cboe Insights! Newsy: Value Investor Weekly Published: 2025-11-13T13:30:02.416Z Source: https://newsyai.com/edition/6c1c2a32-a122-4c71-942c-c95f5799ea54 Archive: https://newsyai.com/newsy/5bbbadf7-1e6d-4c85-a79b-15b39036f33d.md --- # Value Radar: 10 Fresh Ideas + A Full Valuation Deep‑Dive on Cboe Global Markets (CBOE) Date: November 13, 2025 (United States) This research is educational, not investment advice. Every key assumption is sourced and shown so you can audit it. ## 10 new value candidates (quick scan) - Capital One (COF) — Discover merger approvals secured; closing in 2025 positions COF to own both a major issuing platform and a network, with consent orders/fines attached to Discover remediation. Potential long‑run cost/revenue synergies if integration is executed well. ([reuters.com](https://www.reuters.com/business/finance/us-banking-regulators-ok-capital-one-discover-deal-2025-04-18/?utm_source=openai)) - Cboe Global Markets (CBOE) — record Q3‑25 revenue/EPS; portfolio realignment to focus on derivatives and data (exiting listings in U.S./EU, pursuing sales of Australia/Canada). Raised FY25 organic growth outlook; lowered expense guide. Our pick for the deep‑dive below. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) - Travelers (TRV) — excellent Q3‑25: combined ratio 87.3%, strong core income; cycle discipline plus higher investment yields support mid‑teens ROE through the cycle. ([investor.travelers.com](https://investor.travelers.com/newsroom/press-releases/news-details/2025/Travelers-Reports-Excellent-Third-Quarter-and-Year-to-Date-Results/default.aspx?utm_source=openai)) - Valero (VLO) — heavy cash returns in 2025, low net leverage; still levered to healthy U.S. distillate and export spreads with disciplined capex. ([reuters.com](https://www.reuters.com/business/finance/nyse-parent-ices-profit-beats-estimates-volatility-fuels-record-revenue-2025-07-31/?utm_source=openai)) - Publicis (PUB.PA) — data scale-up via Lotame acquisition underpins targeted ads engine; still talking 4–5% organic growth for 2025, with cash redeployed to data/AI. ([reuters.com](https://www.reuters.com/business/media-telecom/publicis-acquire-data-group-lotame-double-individual-profiles-4-billion-2025-03-06/?utm_source=openai)) - Intercontinental Exchange (ICE) — resilient “all‑weather” model; record 2024 cash flow and strong 2025 results across exchanges, data, mortgages; steady capital returns. Good comp to CBOE. ([ir.theice.com](https://ir.theice.com/press/news-details/2025/Intercontinental-Exchange-Reports-Strong-Full-Year-2024-Results/default.aspx?utm_source=openai)) - CME Group (CME) — top‑tier margins, durable interest‑rate/FX/energy complex; 3Q‑25 earnings solid; trades at a premium multiple among exchange peers. Useful comp for CBOE. ([cmegroup.com](https://www.cmegroup.com/media-room/press-releases/2025/10/22/cme_group_inc_announcesthird-quarter2025financialresults.html?utm_source=openai)) - Brookfield (BN) — diversified, asset‑heavy compounder; value tied to fee‑bearing capital growth and monetizations; watch rates and fundraising cadence. (Use as basket with BAM for “sum of parts.”) - Aflac (AFL) — capital‑light, high‑cash‑conversion protection business with strong buybacks/dividend; Japan FX exposure is the swing factor. - eBay (EBAY) — high free cash conversion, buyback‑heavy model; ad take‑rate tailwind; execution on GMV and verticals is key. Now the full deep‑dive. --- # Cboe Global Markets (CBOE): full valuation deep‑dive ## Why this is timely - Q3‑25 was a record quarter: net revenue $605.5M (+14% y/y), GAAP EPS $2.85 (+38%), adjusted EPS $2.67 (+20%). Management raised 2025 organic net revenue growth target to “low double‑digit to mid‑teens” and trimmed expense guidance. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) - Strategic realignment: initiating sales of Cboe Australia and Cboe Canada; discontinuing U.S./EU corporate listings; cost actions in some smaller lines. The company estimates roughly an 8–10% adjusted opex reduction at run‑rate (vs. 2025 guide baseline) with only ~3% net‑revenue impact. Focus is reinforced on proprietary derivatives (SPX/VIX), data, and core cash/spot markets. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) - Exclusive SPX options license with S&P Dow Jones runs through Dec 31, 2032 (exclusive) and 2033 (non‑exclusive), a key moat underpinning SPX/VIX economics. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2013/CBOE-Holdings-And-SP-Dow-Jones-Indices-Extend-Licensing-Agreement-Through-2033-03-13-2013/default.aspx?utm_source=openai)) Bottom line: This is a quality exchange franchise doubling down on its crown jewels (SPX/VIX and data). We test whether today’s price bakes in too much growth. --- ## Business in one page - What they do: Exchange and clearing networks spanning U.S./EU cash equities and ETPs, U.S. and European derivatives (with flagship SPX options and VIX futures/options), global FX, and market‑data/analytics sold under the “Data Vantage” banner. Q3‑25: Derivatives +15% net revenue y/y; Cash & Spot +14%; Data Vantage +12%. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) - Cash engine: 2024 cash from operations (CFO) was $1.10B; capex on PP&E/leasehold ≈ $61M, implying very high free cash conversion. 2024 also included dividends ($249M) and buybacks ($205M). ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374310/000162828025006984/cboe-20241231.htm)) - Shareholder returns: quarterly dividend raised to $0.72 in Q3 and maintained in Q4 2025; 15th consecutive year of increases. Shares outstanding ≈ 104–105M. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Declares-Increased-Third-Quarter-2025-Dividend/default.aspx?utm_source=openai)) Moat pillars we underwrite: - Exclusivity on SPX and the VIX ecosystem (license through 2032/2033). ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374310/000162828025006984/cboe-20241231.htm?utm_source=openai)) - Network effects and liquidity in index options; microstructure and product innovation (e.g., daily expiries in SPXW) sustain activity. ([ww2.cboe.com](https://ww2.cboe.com/tradable_products/sp_500/spx_options/specifications/?utm_source=openai)) - Sticky, high‑margin data subscriptions (Data Vantage). ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) --- ## Cross‑checking the landscape (peers/positioning) - ICE: record multi‑year cash generation; 3Q‑25 net revenues $2.4B, adjusted EPS $1.71; margins near 59% adjusted; robust capital returns. ([ir.theice.com](https://ir.theice.com/press/news-details/2025/Intercontinental-Exchange-Reports-Strong-Third-Quarter-2025/default.aspx?utm_source=openai)) - CME: 3Q‑25 revenue $1.5B, net income $908M; premium valuation relative to peers (mid‑20s trailing P/E; high‑teens EV/EBITDA). ([cmegroup.com](https://www.cmegroup.com/media-room/press-releases/2025/10/22/cme_group_inc_announcesthird-quarter2025financialresults.html?utm_source=openai)) These comps help frame multiples for sanity checks later. --- ## Ground‑up valuation: FCFE DCF + comparables We value equity directly using free cash flow to equity (FCFE) anchored in audited cash flow. Key audited anchors (FY2024 unless noted): - CFO: $1,100.6M; PP&E/leasehold capex ≈ $60.9M. We treat Cboe as structurally low‑capex. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374310/000162828025006984/cboe-20241231.htm)) - Dividends: $249.4M (2024 actual), but note the dividend rose to $0.72/q in 2H25. (Dividends validate cash coverage; for FCFE we value pre‑distribution cash.) ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374310/000162828025006984/cboe-20241231.htm)) - Shares: diluted weighted‑average ≈105.5M in 2024; spot outstanding ≈104.6M late‑2025. We use 105M for per‑share math. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374310/000162828025006984/cboe-20241231.htm)) - Structure: No large capex cycle in guidance; 2025 opex guide trimmed to $827–$842M with higher organic net‑revenue growth (“low double‑digit to mid‑teens”). We conservatively translate this into mid‑single‑digit FCFE growth after 2025. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) How we map CFO to FCFE: - FCFE ≈ CFO – maintenance/growth capex – net working‑capital/other recurring items. For Cboe, CFO already includes interest/taxes and working capital swings (e.g., Section 31 timing). Using multi‑year context, a stable proxy is CFO minus PP&E capex. 2024 FCFE proxy ≈ $1,100.6M – $60.9M ≈ $1,040M. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374310/000162828025006984/cboe-20241231.htm)) Model choices (documented): - Year‑1 FCFE base (2025E): we start at $1,020M–$1,150M to bracket “flat to modestly up” cash under the new focus/expense plan. Base case = $1,050M. Evidence: raised 2025 organic growth and lowered opex guide; capex remains light. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) - Near‑term FCFE growth (Years 1–5): 5–7% (base 6%). Rationale: derivatives and data growth, offset by mix/normalization risk and the realignment removing small revenue streams. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) - Terminal growth: 2.5–3.5% (base 3.0%), consistent with global GDP/inflation and exchange moats. - Cost of equity (discount rate): 8.0–9.0% (base 8.5%), reflecting large‑cap, cash‑rich, oligopolistic market‑infra risk. Cross‑check to peer quality and rate backdrop. ([ir.theice.com](https://ir.theice.com/press/news-details/2025/Intercontinental-Exchange-Reports-Strong-Full-Year-2024-Results/default.aspx?utm_source=openai)) ### DCF math (base case) - FCFE(2025E) = $1,050M; grow at 6% for 5 years; terminal g = 3.0%; r = 8.5%. - PV of Years 1–5 ≈ $4.8B; PV of terminal value ≈ $17.0B; Equity value ≈ $21.8B. - Per share (105M) ≈ $208. We then test two more scenarios: - Upside case: FCFE(2025E) = $1,150M; Years 1–5 growth 7%; g = 3.5%; r = 8.0% → equity ≈ $27–28B → ≈ $255–$265/sh. - Downside case: FCFE(2025E) = $1,020M; Years 1–5 growth 4%; g = 2.5%; r = 9.0% → equity ≈ $18–19B → ≈ $170–$180/sh. Key sensitivities (what moves value most): 1) FCFE level (SPX/VIX activity and pricing; data growth) 2) Discount rate (macro/risk premia) 3) Terminal growth (license/competition outcomes post‑2032) All inputs above are either audited/quantified (CFO, capex, shares), or tied to the company’s 2025 outlook that we translate conservatively to cash growth. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374310/000162828025006984/cboe-20241231.htm)) ### Comparable‑multiples checks - Trailing P/E: CME ≈ mid‑20s; ICE typically high‑teens/low‑20s; CBOE’s trailing P/E around mid‑20s at recent prices. On a peer‑band of ~20–26x and an annualized EPS run‑rate near ~$10–$11 (Q3‑25 GAAP EPS was $2.85), an implied range is roughly $200–$275 before any premium/discount for growth mix. ([cmegroup.com](https://www.cmegroup.com/media-room/press-releases/2025/10/22/cme_group_inc_announcesthird-quarter2025financialresults.html?utm_source=openai)) - EV/EBITDA: CME ~19x TTM; ICE often mid‑ to high‑teens given more diversification; this suggests a quality exchange cohort trading ~16–20x EV/EBITDA. CBOE’s mix shift toward derivatives/data argues for the upper half, but not a peak premium to CME. ([valueinvesting.io](https://valueinvesting.io/CME/valuation/ev_ebitda-multiples?utm_source=openai)) Multiples sanity aligns with our DCF band. --- ## What could change the thesis? Upside levers - Sustained high SPX/VIX volumes, daily expiries adoption, and new product innovation lifting capture rates. ([ww2.cboe.com](https://ww2.cboe.com/tradable_products/sp_500/spx_options/specifications/?utm_source=openai)) - Data Vantage monetization (pricing, new feeds/analytics) and expense discipline ahead of plan. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) - Portfolio sales (Australia/Canada) at attractive multiples with minimal earnings drag. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) Downside risks - License/key‑product concentration: SPX/VIX drive outsized economics; any license dispute or adverse renegotiation beyond 2032 would matter. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374310/000162828025006984/cboe-20241231.htm?utm_source=openai)) - Lower realized volatility for extended periods (VIX complex softness) or competitive inroads in non‑proprietary options. - Regulatory or fee‑structure changes affecting data or market‑access pricing. --- ## Roadmap to value creation (12–24 months) 1) Execute the portfolio realignment - Close asset sales (Australia/Canada), wind down low‑ROI listings, and capture the guided 8–10% opex reduction run‑rate vs. 2025 baseline. Track disclosure on revenue/EBITDA mix post‑actions. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) 2) Reinforce the derivatives flywheel - Keep expanding SPX expiries, micro/mini contracts (e.g., XSP), education, and market‑maker support to deepen liquidity. ([ww2.cboe.com](https://ww2.cboe.com/tradable_products/sp_500/spx_options/specifications/?utm_source=openai)) 3) Grow Data Vantage - Hit the upgraded 2025 organic growth range and articulate 2026–27 pricing/mix ambitions to justify a stickier multiple. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) --- ## Step‑by‑step audit trail (what we did and why) 1) Anchored FCFE to audited CFO ($1,100.6M, 2024) and capex ($60.9M) from the 2024 10‑K; validated cash returns (dividends/buybacks). ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374310/000162828025006984/cboe-20241231.htm)) 2) Incorporated 2025 guidance shifts (raised organic revenue growth; lowered opex) and strategy changes (asset sales, listings exit) from the Oct 31, 2025 release; mapped these to conservative 2025 FCFE and 5‑year growth. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) 3) Confirmed moat duration by checking SPX/VIX licensing terms to 2032/2033. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374310/000162828025006984/cboe-20241231.htm?utm_source=openai)) 4) Cross‑checked comp bands using ICE/CME recent results and market multiples to sanity‑check DCF outputs. ([ir.theice.com](https://ir.theice.com/press/news-details/2025/Intercontinental-Exchange-Reports-Strong-Third-Quarter-2025/default.aspx?utm_source=openai)) --- ## Verdict and valuation range - Valuation range: $170–$265 per share, with a base DCF around ~$208. - What the range means: At today’s typical trading levels for CBOE (late‑October snapshot near ~$246), the stock embeds optimistic assumptions on FCFE growth and/or a lower discount rate than our base. That’s not “expensive at any price,” but risk‑reward skews to execution‑dependent upside. ([stockanalysis.com](https://stockanalysis.com/stocks/cboe/statistics/?utm_source=openai)) - Recommendation: Quality compounder, but for strict value, prefer an entry below ~$210 (a margin of safety to our base DCF and inside peer P/E bands). Accumulate more aggressively ≤$190 if volatility/volumes temporarily compress and price follows. - What would change our view to “buy at market”: evidence that post‑realignment FCFE can sustain ≥$1.2–$1.3B with 6–8% CAGR and that data growth tracks high‑single/low‑double digits for 2026–27. --- ## Appendix: quick peer markers you can monitor - ICE: record 2024 CFO ~$4.6B; 3Q‑25 adjusted EPS $1.71; adj op margin ~59%. If ICE’s multiple expands on mortgage/data growth, it may lift the sector. ([ir.theice.com](https://ir.theice.com/press/news-details/2025/Intercontinental-Exchange-Reports-Strong-Full-Year-2024-Results/default.aspx?utm_source=openai)) - CME: 3Q‑25 EPS $2.49 GAAP ($2.68 adj); trades at a consistent premium multiple (mid‑20s PE; high‑teens EV/EBITDA). Useful ceiling for CBOE’s multiple. ([cmegroup.com](https://www.cmegroup.com/media-room/press-releases/2025/10/22/cme_group_inc_announcesthird-quarter2025financialresults.html?utm_source=openai)) If you want, I can share a compact spreadsheet so you can flex FCFE, discount rate, and terminal growth and see per‑share values across scenarios.